Lei Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lei Yang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Fuxiang Zhou
Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University
4 shared publications Jing Su
Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University
3 shared publicationsWenbo Wang
Hubei Cancer Clinical Study Center, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital, Wuhan University, Wuhan, China
3 shared publications- Han Wu
Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
2 shared publications Juan Zhong
Department of Oncology, Hubei Province Women and Children Hospital, Wuhan, China
2 shared publications- Binlei Liu
National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, Hubei Key Laboratory of Industrial Microbiology, Hubei University of Technology, Wuhan, China
1 shared publication
Latest Publications
- Open Access
- 11 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1986810
Oncolytic viruses in combination cancer therapy: clinical lessons, biomarker-guided strategies, and future treatment directions
Oncolytic viruses (OVs) preferentially infect and replicate within tumors, induce immunogenic cell death, and remodel immune-poor microenvironments to support T-cell infiltration. These features provide a rationale for combining OVs with immune checkpoint blockade, adoptive cellular therapies, bispecific T-cell engagers, cancer vaccines, and innate immune agonists, and for engineering viruses to express immunostimulatory cytokines. Clinical outcomes, however, have been inconsistent. In MASTERKEY-265, adding intratumoral talimogene laherparepvec to pembrolizumab did not significantly improve progression-free or overall survival in advanced melanoma, despite a 62% objective response rate in the preceding 21-patient phase Ib cohort and evidence of increased intratumoral CD8+ T cells and PD-L1 expression. In contrast, single-arm clinical data for RP1 plus nivolumab in anti-PD-1-refractory melanoma showed objective responses, including durable responses in a subset; the U.S. Food and Drug Administration granted accelerated approval for the regimen, but randomized confirmation remains required. Together with the failure of PHOCUS, these findings indicate that benefit is determined by viral platform, tumor immune state, disease and prior-treatment setting, delivery feasibility, and resistance biology rather than immune activation alone. We critically synthesize positive and negative evidence across checkpoint and non-checkpoint strategies and distinguish biomarkers derived from OV studies from those extrapolated from checkpoint-inhibitor trials. Candidate biomarkers and pharmacodynamic readouts are organized into a three-tier research framework covering pretreatment characterization, platform–partner hypotheses, and on-treatment monitoring; their utility for selecting OV-based combinations still requires validation. We further examine delivery barriers, antiviral immunity, tumor heterogeneity and resistance, next-generation vector engineering, and computational approaches to molecularly guided patient selection. Prospective validation in biomarker-stratified, adaptive trials is needed to improve patient selection, match viral platforms with rational partners, and translate biological activity into durable clinical benefit.
- 11 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1986810
Open AccessOncolytic viruses in combination cancer therapy: clinical lessons, biomarker-guided strategies, and future treatment directions
Oncolytic viruses (OVs) preferentially infect and replicate within tumors, induce immunogenic cell death, and remodel immune-poor microenvironments to support T-cell infiltration. These features provide a rationale for combining OVs with immune checkpoint blockade, adoptive cellular therapies, bispecific T-cell engagers, cancer vaccines, and innate immune agonists, and for engineering viruses to express immunostimulatory cytokines. Clinical outcomes, however, have been inconsistent. In MASTERKEY-265, adding intratumoral talimogene laherparepvec to pembrolizumab did not significantly improve progression-free or overall survival in advanced melanoma, despite a 62% objective response rate in the preceding 21-patient phase Ib cohort and evidence of increased intratumoral CD8+ T cells and PD-L1 expression. In contrast, single-arm clinical data for RP1 plus nivolumab in anti-PD-1-refractory melanoma showed objective responses, including durable responses in a subset; the U.S. Food and Drug Administration granted accelerated approval for the regimen, but randomized confirmation remains required. Together with the failure of PHOCUS, these findings indicate that benefit is determined by viral platform, tumor immune state, disease and prior-treatment setting, delivery feasibility, and resistance biology rather than immune activation alone. We critically synthesize positive and negative evidence across checkpoint and non-checkpoint strategies and distinguish biomarkers derived from OV studies from those extrapolated from checkpoint-inhibitor trials. Candidate biomarkers and pharmacodynamic readouts are organized into a three-tier research framework covering pretreatment characterization, platform–partner hypotheses, and on-treatment monitoring; their utility for selecting OV-based combinations still requires validation. We further examine delivery barriers, antiviral immunity, tumor heterogeneity and resistance, next-generation vector engineering, and computational approaches to molecularly guided patient selection. Prospective validation in biomarker-stratified, adaptive trials is needed to improve patient selection, match viral platforms with rational partners, and translate biological activity into durable clinical benefit.
- Open Access
- 14 June 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (6) , 693
Exploring the Molecular Mechanism of Comorbidity of Type 2 Diabetes Mellitus and Colorectal Cancer: Insights from Bulk Omics and Single-Cell Sequencing Validation
The relationship between type 2 diabetes mellitus (T2DM) and colorectal cancer (CRC) has long been extensively recognized, but their crosstalk mechanisms based on gene regulation remain elusive. In our study, for the first time, bulk RNA-seq and single-cell RNA-seq data were used to explore the shared molecular mechanisms between T2DM and CRC. Moreover, Connectivity Map and molecular docking were employed to determine potential drugs targeting the candidate targets. Eight genes (EVPL, TACSTD2, SOX4, ETV4, LY6E, MLXIPL, ENTPD3, UGP2) were identified as characteristic comorbidity genes for T2DM and CRC, with EVPL and ENTPD3 further identified as core comorbidity genes. Our results demonstrated that upregulation of EVPL and downregulation of ENTPD3 were intrinsic molecular features throughout T2DM and CRC and were significantly associated with immune responses, immune processes, and abnormal immune landscapes in both diseases. Single-cell analysis highlighted a cancer-associated fibroblast (CAF) subset that specifically expressed ENTPD3 in CRC, which exhibited high heterogeneity and unique tumor-suppressive features that were completely different from classical cancer-promoting CAFs. Furthermore, ENTPD3+ CAFs could notably predict immunotherapy response in CRC, holding promise to be an immunotherapy biomarker at the single-cell level. Finally, we identified that droperidol may be a novel drug simultaneously targeting EVPL and ENTPD3. In conclusion, previous studies have often focused solely on metabolic alterations common to T2DM and CRC. Our study establishes EVPL and ENTPD3 as characteristic molecules and immune biomarkers of comorbidity in T2DM and CRC patients, and emphasizes the importance of considering immunological mechanisms in the co-development of T2DM and CRC.
- 14 June 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (6) , 693
Open AccessExploring the Molecular Mechanism of Comorbidity of Type 2 Diabetes Mellitus and Colorectal Cancer: Insights from Bulk Omics and Single-Cell Sequencing Validation
The relationship between type 2 diabetes mellitus (T2DM) and colorectal cancer (CRC) has long been extensively recognized, but their crosstalk mechanisms based on gene regulation remain elusive. In our study, for the first time, bulk RNA-seq and single-cell RNA-seq data were used to explore the shared molecular mechanisms between T2DM and CRC. Moreover, Connectivity Map and molecular docking were employed to determine potential drugs targeting the candidate targets. Eight genes (EVPL, TACSTD2, SOX4, ETV4, LY6E, MLXIPL, ENTPD3, UGP2) were identified as characteristic comorbidity genes for T2DM and CRC, with EVPL and ENTPD3 further identified as core comorbidity genes. Our results demonstrated that upregulation of EVPL and downregulation of ENTPD3 were intrinsic molecular features throughout T2DM and CRC and were significantly associated with immune responses, immune processes, and abnormal immune landscapes in both diseases. Single-cell analysis highlighted a cancer-associated fibroblast (CAF) subset that specifically expressed ENTPD3 in CRC, which exhibited high heterogeneity and unique tumor-suppressive features that were completely different from classical cancer-promoting CAFs. Furthermore, ENTPD3+ CAFs could notably predict immunotherapy response in CRC, holding promise to be an immunotherapy biomarker at the single-cell level. Finally, we identified that droperidol may be a novel drug simultaneously targeting EVPL and ENTPD3. In conclusion, previous studies have often focused solely on metabolic alterations common to T2DM and CRC. Our study establishes EVPL and ENTPD3 as characteristic molecules and immune biomarkers of comorbidity in T2DM and CRC patients, and emphasizes the importance of considering immunological mechanisms in the co-development of T2DM and CRC.
- Open Access
- 1 April 2024
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 117 (C) , 109478
Histologic transformation of rectal adenocarcinoma to choriocarcinoma after surgery and chemotherapy: A rare case report and review of the literature
Introduction and importance: Choriocarcinoma is a rapidly progressive, widely metastatic, β-human chorionic gonadotropin (β-hCG)-secreting malignant tumor originating from trophoblast cells. Most choriocarcinomas are pregnancy-related. Choriocarcinoma of nonpregnant origin is very rare. Case presentation: A 60-year-old woman underwent abdominopelvic resection (APR) for low rectal cancer in May 2020. Postoperative pathological findings showed a poorly differentiated adenocarcinoma. Because of a post-operative recurrence, then she underwent chemotherapy for rectal adenocarcinoma. In February 2021, imaging finding showed metastases in her liver, both lungs and pelvis. Surprisingly, the β-hCG level was significantly elevated. A transvaginal pelvic tumor biopsy was performed and the pathology report was presented after discussions: choriocarcinoma differentiated carcinoma was considered, with no adenocarcinoma component detected. Then the patient underwent chemotherapy regimens for choriocarcinoma, which were initially effective but quickly became resistant. The patient died 8 months after the diagnosis of adenocarcinoma of the rectum transformed into choriocarcinoma. Clinical discussion: The dedifferentiation of adenocarcinoma to choriocarcinoma is rarely diagnosed and the disease is often overlooked, leading to delays in diagnosis and treatment, documenting cases and their clinical outcomes is important for future research and to improve patient prognosis. Perhaps genomic assessment using next-generation sequencing (NGS) technology could help in diagnosis and guide therapeutic strategies. Conclusion: We report a very rare case of non-pregnant choriocarcinoma transformed from primary rectal adenocarcinoma. Awareness of secondary biopsies in special cases and genetic testing based on the dynamics of the disease should be raised in clinical practice to better develop precise treatment plans. Highlights:
- 1 April 2024
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 117 (C) , 109478
Open AccessHistologic transformation of rectal adenocarcinoma to choriocarcinoma after surgery and chemotherapy: A rare case report and review of the literature
Introduction and importance: Choriocarcinoma is a rapidly progressive, widely metastatic, β-human chorionic gonadotropin (β-hCG)-secreting malignant tumor originating from trophoblast cells. Most choriocarcinomas are pregnancy-related. Choriocarcinoma of nonpregnant origin is very rare. Case presentation: A 60-year-old woman underwent abdominopelvic resection (APR) for low rectal cancer in May 2020. Postoperative pathological findings showed a poorly differentiated adenocarcinoma. Because of a post-operative recurrence, then she underwent chemotherapy for rectal adenocarcinoma. In February 2021, imaging finding showed metastases in her liver, both lungs and pelvis. Surprisingly, the β-hCG level was significantly elevated. A transvaginal pelvic tumor biopsy was performed and the pathology report was presented after discussions: choriocarcinoma differentiated carcinoma was considered, with no adenocarcinoma component detected. Then the patient underwent chemotherapy regimens for choriocarcinoma, which were initially effective but quickly became resistant. The patient died 8 months after the diagnosis of adenocarcinoma of the rectum transformed into choriocarcinoma. Clinical discussion: The dedifferentiation of adenocarcinoma to choriocarcinoma is rarely diagnosed and the disease is often overlooked, leading to delays in diagnosis and treatment, documenting cases and their clinical outcomes is important for future research and to improve patient prognosis. Perhaps genomic assessment using next-generation sequencing (NGS) technology could help in diagnosis and guide therapeutic strategies. Conclusion: We report a very rare case of non-pregnant choriocarcinoma transformed from primary rectal adenocarcinoma. Awareness of secondary biopsies in special cases and genetic testing based on the dynamics of the disease should be raised in clinical practice to better develop precise treatment plans. Highlights:
- Open Access
- 23 January 2023
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 21 (1) , 1-9
The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study
Nab-paclitaxel plus gemcitabine (AG) and modified FOLFIRINOX (FFX) are two systemic therapies that have been widely used as standard first-line chemotherapy regimens in metastatic pancreatic cancer. However, since there is no clinical trial to directly compare the efficacy and safety of the two regimens, it is not clear which regimen is more effective. In this study, we aim to examine and compare the efficacy and safety of AG and FFX as first-line chemotherapy regimens in Chinese patients with metastatic pancreatic cancer in a real-world setting. We retrospectively evaluated the outcomes of 44 patients who were diagnosed with metastatic pancreatic cancer and were treated with either AG (n = 24) or FFX (n = 20) as first-line chemotherapy between March 2017 and February 2022 at Zhongnan Hospital of Wuhan University. Prognostic nutrition index (PNI) was calculated based on the serum albumin level and peripheral lymphocyte count. According to the optimal cutoff value of PNI, patients were divided into low PNI group (PNI < 43.70) and high PNI group (PNI ≥ 43.70). Of 44 patients in this study, 24 were treated with AG, and 20 were treated with FFX as first-line chemotherapy. No significant differences in baseline characteristics were found between the two groups. The objective response rate (ORR) was 16.7% in the AG group and 20.0% in the FFX group. The disease control rate (DCR) was 70.8% in the AG group and 60.0% in the FFX group. There was no significant difference in PFS or OS between the AG group and the FFX group. The median progression-free survival (PFS) was 4.67 months (95% confidence interval [CI], 2.91–6.42) in the AG group and 3.33 months (95% CI, 1.87–4.79, p = 0.106) in the FFX group. The median overall survival (OS) was 9.00 months (95% CI, 7.86–12.19) in the AG group and 10.00 months (95% CI, 7.70–12.27, p = 0.608) in the FFX group. The second-line treatment rate was 62.5% in the AG group and 55.0% in the FFX group. Immune checkpoint inhibitors (ICIs) based regimens are common second-line treatment options whether in AG or FFX group. Significantly more grade 3–4 peripheral neuropathy occurred in the AG than FFX groups (4 (20.8%) vs 0 (0.0%), p = 0.030*). The patients in the PNI (Prognostic nutrition index) ≥ 43.7 group had a significant longer median OS (PNI ≥ 43.7 vs PNI < 43.7: 10.33 vs 8.00 months, p = 0.019). AG and FFX showed comparable efficacy outcomes in patients with metastatic pancreatic cancer. Pancreatic cancer patients receiving first-line chemotherapy with good nutritional status are likely to have a better prognosis.
- 23 January 2023
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 21 (1) , 1-9
Open AccessThe efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study
Nab-paclitaxel plus gemcitabine (AG) and modified FOLFIRINOX (FFX) are two systemic therapies that have been widely used as standard first-line chemotherapy regimens in metastatic pancreatic cancer. However, since there is no clinical trial to directly compare the efficacy and safety of the two regimens, it is not clear which regimen is more effective. In this study, we aim to examine and compare the efficacy and safety of AG and FFX as first-line chemotherapy regimens in Chinese patients with metastatic pancreatic cancer in a real-world setting. We retrospectively evaluated the outcomes of 44 patients who were diagnosed with metastatic pancreatic cancer and were treated with either AG (n = 24) or FFX (n = 20) as first-line chemotherapy between March 2017 and February 2022 at Zhongnan Hospital of Wuhan University. Prognostic nutrition index (PNI) was calculated based on the serum albumin level and peripheral lymphocyte count. According to the optimal cutoff value of PNI, patients were divided into low PNI group (PNI < 43.70) and high PNI group (PNI ≥ 43.70). Of 44 patients in this study, 24 were treated with AG, and 20 were treated with FFX as first-line chemotherapy. No significant differences in baseline characteristics were found between the two groups. The objective response rate (ORR) was 16.7% in the AG group and 20.0% in the FFX group. The disease control rate (DCR) was 70.8% in the AG group and 60.0% in the FFX group. There was no significant difference in PFS or OS between the AG group and the FFX group. The median progression-free survival (PFS) was 4.67 months (95% confidence interval [CI], 2.91–6.42) in the AG group and 3.33 months (95% CI, 1.87–4.79, p = 0.106) in the FFX group. The median overall survival (OS) was 9.00 months (95% CI, 7.86–12.19) in the AG group and 10.00 months (95% CI, 7.70–12.27, p = 0.608) in the FFX group. The second-line treatment rate was 62.5% in the AG group and 55.0% in the FFX group. Immune checkpoint inhibitors (ICIs) based regimens are common second-line treatment options whether in AG or FFX group. Significantly more grade 3–4 peripheral neuropathy occurred in the AG than FFX groups (4 (20.8%) vs 0 (0.0%), p = 0.030*). The patients in the PNI (Prognostic nutrition index) ≥ 43.7 group had a significant longer median OS (PNI ≥ 43.7 vs PNI < 43.7: 10.33 vs 8.00 months, p = 0.019). AG and FFX showed comparable efficacy outcomes in patients with metastatic pancreatic cancer. Pancreatic cancer patients receiving first-line chemotherapy with good nutritional status are likely to have a better prognosis.
- Open Access
- 13 December 2022
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 75 (2) , 696-706
Prognostic Nutritional Index Associates with Immunotherapy Response in Patients with Metastatic Biliary Tract Cancer
Purpose: The present study aims to evaluate the effect of prognostic nutrition index (PNI) on the response and prognosis of patients with metastatic biliary tract cancer (BTC) patients treated with immunotherapy.Methods: The outcomes of 83 patients with metastatic BTC were evaluated retrospectively. Among them, 51 received immune checkpoint inhibitors (ICIs) treatment (ICIs cohort) and 32 patients received first-line chemotherapy (chemotherapy cohort). According to the optimal cutoff value of PNI, patients in ICIs cohort were divided into low PNI group (PNI < 44.30) and high PNI group (PNI≥ 44.30).Results: Patients received first-line immunotherapy-based combination antitumor therapy in ICIs cohort showed significant longer median PFS and OS contrast with first-line chemotherapy cohort. In ICIs cohort, median PFS and OS were significantly longer in the high PNI group. In addition, multivariate Cox regression analysis showed that high PNI was an independent risk factor for median PFS (hazard ratio (HR), 0.474, 95% CI, 0.246–0.910; P = 0.025) and median OS (HR, 0.229, 95% CI, 0.097–0.539; P = 0.001) in ICIs cohort, respectively. Conclusion: Our study provides preliminary evidence that immunotherapy for metastatic BTC is effective and safe. PNI was an independent prognostic indicator of median PFS and OS in patients with metastatic BTC receiving immunotherapy.
- 13 December 2022
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 75 (2) , 696-706
Open AccessPrognostic Nutritional Index Associates with Immunotherapy Response in Patients with Metastatic Biliary Tract Cancer
Purpose: The present study aims to evaluate the effect of prognostic nutrition index (PNI) on the response and prognosis of patients with metastatic biliary tract cancer (BTC) patients treated with immunotherapy.Methods: The outcomes of 83 patients with metastatic BTC were evaluated retrospectively. Among them, 51 received immune checkpoint inhibitors (ICIs) treatment (ICIs cohort) and 32 patients received first-line chemotherapy (chemotherapy cohort). According to the optimal cutoff value of PNI, patients in ICIs cohort were divided into low PNI group (PNI < 44.30) and high PNI group (PNI≥ 44.30).Results: Patients received first-line immunotherapy-based combination antitumor therapy in ICIs cohort showed significant longer median PFS and OS contrast with first-line chemotherapy cohort. In ICIs cohort, median PFS and OS were significantly longer in the high PNI group. In addition, multivariate Cox regression analysis showed that high PNI was an independent risk factor for median PFS (hazard ratio (HR), 0.474, 95% CI, 0.246–0.910; P = 0.025) and median OS (HR, 0.229, 95% CI, 0.097–0.539; P = 0.001) in ICIs cohort, respectively. Conclusion: Our study provides preliminary evidence that immunotherapy for metastatic BTC is effective and safe. PNI was an independent prognostic indicator of median PFS and OS in patients with metastatic BTC receiving immunotherapy.
- Open Access
- 22 August 2022
- Published by Springer Nature in Research Square
The Efficacy and Safety of Nab-Paclitaxel Plus Gemcitabine versus mFOLFIRINOX in the First-Line Treatment of Metastatic Pancreatic Cancer: A Retrospective Study.
Background Nab-paclitaxel plus Gemcitabine (AG) and modified FOLFIRINOX (FFX) are two systemic therapies that have been widely used as standard first-line chemotherapy regimens in metastatic pancreatic cancer. However, since there is no clinical trial to directly compare the efficacy and safety of the two regimens, it is not clear which regimen is more effective. In this study, we aim to examine and compare the efficacy and safety of AG and FFX as first-line chemotherapy regimens in Chinese patients with metastatic pancreatic cancer in a real-world setting. Methods We retrospectively evaluated the outcomes of 41 patients who diagnosed with metastatic pancreatic cancer and were treated with either AG (n = 21) or FFX (n = 20) as first-line chemotherapy between March 2017 and February 2022 at Zhongnan hospital of Wuhan University. Results Of 41 patients in this study, 21 were treated with AG and 20 were treated with FFX as first-line chemotherapy. No significant differences in baseline characteristics were found between the two groups. The objective response rate (ORR)was 14.3% in the AG group and 20.0% in the FFX group. The disease control rate (DCR) was 71.4% in the AG group and 60.0% in the FFX group. There was no significant difference in PFS or OS between the AG group and the FFX group.The median progression-free survival (PFS) was 5.27 months (95% confidence interval [CI], 4.08–6.46) in the AG group and 3.67 months (95% CI, 2.28–5.05, p = 0.192)in the FFX group.The median overall survival (OS) was 10.03 months (95% CI, 7.33–12.63) in the AG group and 9.02 months (95% CI,6.02–11.98, p = 0.464) in the FFX group.The second-line treatment rate was 47.1% in the AG group and 55.0% in the FFX group. Immune checkpoint inhibitors (ICIs) based regimens are common second-line treatment options whether in AG or FFX group. Significantly more grade 3–4 peripheral neuropathy occurred in the AG than the FFX groups (4 (19.0%) vs 0 (0.0%), p = 0.040*).The patients in the PNI(Prognostic nutrition index) ≥ 45 group had a significant longer median OS (PNI ≥ 45 vs PNI < 45: 10.34 vs 6.90 mo, P = 0.005). Conclusion AG and FFX showed comparable efficacy outcomes in patients with metastatic pancreatic cancer. Pancreatic cancer patients receiving first-line chemotherapy with good nutritional status are likely to have a better prognosis.
- 22 August 2022
- Published by Springer Nature in Research Square
Open AccessThe Efficacy and Safety of Nab-Paclitaxel Plus Gemcitabine versus mFOLFIRINOX in the First-Line Treatment of Metastatic Pancreatic Cancer: A Retrospective Study.
Background Nab-paclitaxel plus Gemcitabine (AG) and modified FOLFIRINOX (FFX) are two systemic therapies that have been widely used as standard first-line chemotherapy regimens in metastatic pancreatic cancer. However, since there is no clinical trial to directly compare the efficacy and safety of the two regimens, it is not clear which regimen is more effective. In this study, we aim to examine and compare the efficacy and safety of AG and FFX as first-line chemotherapy regimens in Chinese patients with metastatic pancreatic cancer in a real-world setting. Methods We retrospectively evaluated the outcomes of 41 patients who diagnosed with metastatic pancreatic cancer and were treated with either AG (n = 21) or FFX (n = 20) as first-line chemotherapy between March 2017 and February 2022 at Zhongnan hospital of Wuhan University. Results Of 41 patients in this study, 21 were treated with AG and 20 were treated with FFX as first-line chemotherapy. No significant differences in baseline characteristics were found between the two groups. The objective response rate (ORR)was 14.3% in the AG group and 20.0% in the FFX group. The disease control rate (DCR) was 71.4% in the AG group and 60.0% in the FFX group. There was no significant difference in PFS or OS between the AG group and the FFX group.The median progression-free survival (PFS) was 5.27 months (95% confidence interval [CI], 4.08–6.46) in the AG group and 3.67 months (95% CI, 2.28–5.05, p = 0.192)in the FFX group.The median overall survival (OS) was 10.03 months (95% CI, 7.33–12.63) in the AG group and 9.02 months (95% CI,6.02–11.98, p = 0.464) in the FFX group.The second-line treatment rate was 47.1% in the AG group and 55.0% in the FFX group. Immune checkpoint inhibitors (ICIs) based regimens are common second-line treatment options whether in AG or FFX group. Significantly more grade 3–4 peripheral neuropathy occurred in the AG than the FFX groups (4 (19.0%) vs 0 (0.0%), p = 0.040*).The patients in the PNI(Prognostic nutrition index) ≥ 45 group had a significant longer median OS (PNI ≥ 45 vs PNI < 45: 10.34 vs 6.90 mo, P = 0.005). Conclusion AG and FFX showed comparable efficacy outcomes in patients with metastatic pancreatic cancer. Pancreatic cancer patients receiving first-line chemotherapy with good nutritional status are likely to have a better prognosis.
- 18 July 2013
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 58 (11) , 3189-3197
Knockdown of Inhibitor of Growth Protein 2 Inhibits Cell Invasion and Enhances Chemosensitivity to 5-FU in Human Gastric Cancer Cells
- 18 July 2013
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 58 (11) , 3189-3197
Knockdown of Inhibitor of Growth Protein 2 Inhibits Cell Invasion and Enhances Chemosensitivity to 5-FU in Human Gastric Cancer Cells